<DOC>
	<DOCNO>NCT01204099</DOCNO>
	<brief_summary>Phase 1 : To determine maximally tolerate dose ( MTD ) recommend dose ( RD ) potential efficacy PX-866 combination docetaxel patient solid tumor . Phase 2 : To determine antitumor activity safety PX-866 combination docetaxel versus docetaxel alone patient NSCLC SCCHN .</brief_summary>
	<brief_title>Study PX-866 Docetaxel Solid Tumors</brief_title>
	<detailed_description>This Phase 1/2 open-label study . In Phase 1 part study , PX-866 give combination docetaxel patient incurable locally advanced , recurrent metastatic cancer . Phase 2 study open-label , randomize evaluation antitumor activity safety PX-866 , administer MTD/RD identify Phase 1 ( 8mg daily ) , combination docetaxel versus docetaxel alone patient locally advance , recurrent , metastatic NSCLC ( Group 1 ) patient locally advance , recurrent , metastatic SCCHN ( Group 2 ) . Group 1 ( patient locally advance , recurrent , metastatic NSCLC ) close enrollment . All treatment administer 21-day cycle . Docetaxel 75 mg/m2 administer IV Day 1 21-day cycle . PX-866 administer orally via PEG tube ( applicable ) per day Days 1 21 treatment cycle patient randomize treatment arm contain PX-866 . Patients evaluated progression approximately every 6 week . Patients stable disease ( SD ) good , per investigator assessment , receive repeat cycle treatment 21-day schedule disease progression , unacceptable toxicity withdrawal consent .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>At least 18 year time consent Agrees use medically accept form contraception time consent completion follow study visit If female child bear potential , negative pregnancy test ( require post menopausal female ) Signed informed consent document approve institutional review board independent ethic committee ( IRB/IEC ) Has either locally advance , recurrent , metastatic NSCLC receive least 1 2 prior systemic treatment regimen may include 1 platinum base chemotherapy regimen and/or epidermal growth factor receptor ( EGFR ) inhibitor OR locally advance , recurrent metastatic SCCHN receive least one two prior systemic treatment regimen . Measurable disease per Response Evaluation Criteria In Solid Tumors Eastern Cooperative Oncology Group ( ECOG ) 0 1 In opinion clinical investigator , life expectancy &gt; 3 month Adequate hematologic function define : Hemoglobin ≥ 9 g/dL Absolute neutrophil count ( ANC ) ≥1500 cells/µL Platelets ≥100,000/µL Adequate hepatic function define follow : Bilirubin ≤ ULN Aspartate aminotransaminase ( AST/SGOT ) alanine aminotransferase ( ALT/SGPT ) ≤1.5 x upper limit normal ( ULN ) Creatinine level ≤1.5 x ULN Has medical , social , psychosocial factor , opinion investigator , could impact safety compliance study procedure Is breastfeed Treatment systemic chemotherapy , epidermal growth factor receptor ( EGFR ) inhibitor , radiation experimental agent within 4 week study drug dosing . Washout period follow palliative radiation discuss study medical monitor Previous treatment docetaxel except patient Phase 2 receive docetaxel contain regimen part adjuvant neoadjuvant therapy complete least 6 month prior study drug dose Previous treatment phosphatidylinositol 3 kinase ( PI 3K ) inhibitor Known human immunodeficiency virus ( HIV ) Known suspect clinically active brain metastasis . Previously treat stable brain metastasis allowable . Stable brain metastasis define change CT scan MRI minimum two month AND change steroid dose minimum four week , unless change due intercurrent infection acute event Grade &gt; 2 peripheral neuropathy , define National Cancer Institute ( NCI ) Common Terminology Criteria Adverse Events ( CTCAE ) , Version 4.02 Any significant medical psychiatric condition opinion investigator render patient inadequate participation History severe hypersensitivity reaction docetaxel drug formulate polysorbate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>PX-866</keyword>
	<keyword>Non small cell lung cancer</keyword>
	<keyword>solid tumor</keyword>
	<keyword>Squamous cell cancer head neck</keyword>
	<keyword>docetaxel</keyword>
	<keyword>NSCLC</keyword>
	<keyword>taxotere</keyword>
	<keyword>SCCHN</keyword>
	<keyword>PI-3K</keyword>
	<keyword>PI3 kinase</keyword>
	<keyword>PI3K</keyword>
</DOC>